Car-T therapies and ADCs feature among recent first-in-human study entrants.
ApexOnco Front Page
Recent articles
The agency approved eight oncology products over the month.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Inclacumab fails, and osivelotor is on hold.
J&J, Astra, Pfizer and others move yet more ADCs into human studies.
Shortly after ponsegromab, visugromab is to start phase 2/3.
Progress with three bispecific molecules is rewarded with a $120m equity raise.
Meanwhile, ASK Pharm challenges Hutchmed in cMet.
